COMMUNIQUÉS West-GlobeNewswire

Vistin Pharma ASA: Third quarter and YTD 2025 financial results
31/10/2025
Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31 st of October 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025. Revenue in the third [...]
Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ® 25 and 50 mg
31/10/2025
Second API manufacturing facility added to ensure supply for patients with insomnia in Japan and for future demand across the Asia-Pacific region Expected to improve profitability through manufacturing cost reductions [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025
31/10/2025
Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine [...]
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
31/10/2025
4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration Up to $336 [...]
InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC ICP-B794 in China
31/10/2025
BEIJING, Oct. 30, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first [...]
MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication
31/10/2025
Study published in the Journal of Atherosclerosis and Thrombosis demonstrates tipelukast (MN-001 and its metabolite MN-002) has influence on cholesterol metabolism in patients LA JOLLA, Calif., Oct. 30, 2025 (GLOBE [...]
Bright Minds Biosciences to Present at Upcoming Conferences
30/10/2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the [...]
BBOT Announces Poster Presentations at the San Antonio Breast Cancer Symposium (SABCS)
30/10/2025
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today [...]
Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025
30/10/2025
Nyxoah to Release Third Quarter 2025 Financial Results on November 13, 2025 Mont-Saint-Guibert, Belgium – Thursday, October 30, 2025, 10:10pm CET / 5:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the [...]
Nyxoah Publiera ses Résultats Financiers du Troisième Trimestre 2025 le 13 Novembre 2025
30/10/2025
Nyxoah Publiera ses Résultats Financiers du Troisième Trimestre 2025 le 13 Novembre 2025 Mont-Saint-Guibert, Belgique – 30 octobre 2025, 22h10 CET / 17h10 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou [...]
MEDIROM MOTHER Labs Inc. Receives Capital Investment from Internal Investors
30/10/2025
Completion of Private Placement of New Shares as Part of Series A Round Valued at ¥9 Billion TOKYO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- MEDIROM MOTHER Labs Co., Ltd. (Headquarters: Minato-ku, Tokyo; President and CEO: [...]
Rapid Micro Biosystems to Participate in the Stifel 2025 Healthcare Conference
30/10/2025
LEXINGTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to [...]
Corbus Pharmaceuticals Announces Proposed Public Offering
30/10/2025
NORWOOD, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced that it plans to offer and sell shares [...]
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
30/10/2025
Châtillon, France, October 30, 2025 DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (the “Company” or “DBV [...]
DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Conseil d’administration
30/10/2025
Châtillon, France, 30 octobre 2025 DBV Technologies annonce la nomination de Philina Lee, Ph.D. au sein de son Conseil d’administration DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), (la « [...]
Olema Oncology to Present Trial-in-Progress Poster for Phase 3 OPERA-02 Trial of Palazestrant Plus Ribociclib at SABCS 2025
30/10/2025
SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Primary Care Physician Use of Counterpart Assistant (CA) Technology Associated With Earlier Diagnosis And Less Frequent Hospitalization In Underserved Populations
30/10/2025
New whitepaper demonstrates how CA enables primary care teams in resource-constrained settings to prevent, detect, and manage chronic disease. SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“ [...]
Artiva Biotherapeutics to Participate in Upcoming Investor Conferences in November
30/10/2025
SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients [...]
Certara Expands Biosimulation Market with AI-Driven QSP Platform
30/10/2025
Certara IQ™ integrates AI and biosimulation to accelerate R&D productivity, reduce risk, and deepen understanding of novel and complex therapies RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: [...]

Pages